According to the World Health Organization (WHO), undesirable effects are classified according to their frequency of development as follows: very often (≥ 1/10), often (≥ 1/100, <1/10), infrequently (≥ 1/1000, <1/100), rarely (≥ 1/10000, <1/1000) and very rarely (<1/10000); frequency is unknown (the frequency of occurrence of phenomena can not be determined on the basis of available data).
From the heart
often: bradycardia;
rarely: progression of heart failure, orthostatic hypotension, tachycardia, the onset of Raynaud's syndrome;
rarely: atrioventricular blockade.
From the side of the vessels
often: cooling of extremities, progression of "intermittent" lameness in patients with Raynaud's syndrome.
From the central nervous system
infrequently: sleep disturbance;
rarely: dizziness, headache, nightmarish dreams, fatigue, paresthesia, confusion, hallucinations, psychosis, emotional lability.
From the side of the organ of vision
rarely: dryness of the mucous membrane of the eye, impaired vision.
From the digestive system
often: dyspeptic disorders (nausea, pain and spasm in the epigastric region, diarrhea, coprostasis);
rarely: dryness of the oral mucosa, hepatotoxicity with intrahepatic cholestasis, jaundice, pancreatitis;
frequency is unknown: constipation.
On the part of the hematopoiesis system
rarely: purpura, thrombocytopenia, leukopenia, hemorrhagic rash;
From the skin
rarely: skin rash, alopecia, psoriasis-like skin reactions, exacerbation of psoriasis.
From the genitourinary system
rarely: impotence.
From the respiratory system
rarely: syncope, the appearance of bronchospasm in patients with bronchial asthma, or having an indication of bronchospasm in the anamnesis.
Laboratory indicators
often: hyponatremia, hypokalemia, hyperuricemia, hyperglycemia and glucosuria, impaired glucose tolerance;
infrequently: increased activity of "hepatic" transaminases in the blood serum;
rarely: an increase in the titer of antinuclear antibodies.
Post-marketing use also reported the following side effects: increased activity of liver transaminases and / or bilirubin, Peyronie's disease, sinus node weakness syndrome, lupus syndrome (as in other beta-blockers), anorexia, stomach irritation, vomiting , convulsions, jaundice (intrahepatic cholestatic jaundice), vertigo, xanthopsia, agranulocytosis, aplastic anemia, photosensitivity, necrotizing angiitis (vasculitis, cutaneous vasculitis), Lyell's syndrome (toxic s epidermal necrolysis), hyperglycemia, glycosuria, muscle spasm, weakness, restlessness.